



(12) **CORRECTED EUROPEAN PATENT SPECIFICATION**

(15) Correction information:
Corrected version no 2 (W2 B1)
Corrections, see
Bibliography INID code(s) 74

(48) Corrigendum issued on:
28.10.2020 Bulletin 2020/44

(45) Date of publication and mention
of the grant of the patent:
26.08.2020 Bulletin 2020/35

(21) Application number: **14874099.6**

(22) Date of filing: **29.12.2014**

(51) Int Cl.:
A61K 38/17 ^(2006.01) **C07K 14/47** ^(2006.01)
A61K 39/00 ^(2006.01) **A61K 45/06** ^(2006.01)
A61K 31/436 ^(2006.01) **A61K 31/519** ^(2006.01)
A61K 31/573 ^(2006.01) **C12N 15/62** ^(2006.01)
A61P 37/02 ^(2006.01) **A61P 37/06** ^(2006.01)
A61P 25/28 ^(2006.01) **A61P 29/00** ^(2006.01)

(86) International application number:
PCT/US2014/072484

(87) International publication number:
WO 2015/100446 (02.07.2015 Gazette 2015/26)

(54) **METHODS AND COMPOSITIONS RELATING TO P62/SQSTM1 FOR THE TREATMENT AND PREVENTION OF INFLAMMATION-ASSOCIATED DISEASES**

VERFAHREN UND ZUSAMMENSETZUNGEN IM ZUSAMMENHANG MIT P62/SQSTM1 ZUR
BEHANDLUNG UND PRÄVENTION VON ENTZÜNDUNGSBEDINGTEN ERKRANKUNGEN

MÉTHODES ET COMPOSITIONS RELATIVES À P62/SQSTM1 POUR TRAITER ET PRÉVENIR LES
MALADIES ASSOCIÉES À UNE INFLAMMATION

(84) Designated Contracting States:
**AL AT BE BG CH CY CZ DE DK EE ES FI FR GB
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO
PL PT RO RS SE SI SK SM TR**

(30) Priority: **29.12.2013 US 201361921504 P**
07.03.2014 US 201461949597 P

(43) Date of publication of application:
09.11.2016 Bulletin 2016/45

(73) Proprietor: **Curelab Oncology, Inc.**
Dedham MA 02026 (US)

(72) Inventors:
• **VENANZI, Franco**
62032 Camerino MC (IT)
• **CONCETTI, Antonio**
63837 Falerone FM (IT)
• **SABBIETI, Maria Giovanna**
62032 Camerino MC (IT)
• **AGAS, Dimitrios**
62032 Camerino MC (IT)

• **GABAI, Vladimir**
Brighton, Massachusetts 02135 (US)
• **SHIFRIN, Victor**
Newton, Massachusetts 02466 (US)
• **SHERMAN, Michael**
Newton, Massachusetts 02459 (US)
• **SHNEIDER, Alexander**
Needham, Massachusetts 02492 (US)

(74) Representative: **Benatov, Samuil Gabriel**
Dr. EMIL BENATOV & PARTNERS
6, Asen Peykov Str.
1113 Sofia (BG)

(56) References cited:
WO-A1-2007/044522 WO-A2-2005/050170
WO-A2-2011/039734 CA-A1- 2 844 283
US-A- 5 977 311 US-A1- 2006 035 823
US-A1- 2009 215 895 US-A1- 2012 295 800
US-B1- 6 291 645

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- | | |
|---|---|
| <ul style="list-style-type: none"> • GEETHA THANGIAH ET AL: "Sequestosome 1/p62: across diseases", BIOMARKERS : BIOCHEMICAL INDICATORS OF EXPOSURE, RESPONSE, AND SUSCEPTIBILITY TO CHEMI, TAYLOR & FRANCIS, UK, vol. 17, no. 2, 1 March 2012 (2012-03-01), pages 99-103, XP008164216, ISSN: 1366-5804, DOI: 10.3109/1354750X.2011.653986 • PARK SANGWOOK ET AL: "p62/SQSTM1 Enhances NOD2-Mediated Signaling and Cytokine Production through Stabilizing NOD2 Oligomerization", PLOS ONE, vol. 8, no. 2, February 2013 (2013-02), XP055384144, ISSN: 1932-6203 | <ul style="list-style-type: none"> • SABBIETI MARIA GIOVANNA ET AL: "Plasmid DNA-coding p62 as a bone effective anti-inflammatory/anabolic agent", ONCOTARGET, vol. 6, no. 6, February 2015 (2015-02), pages 3590-3599, XP055384300, |
|---|---|